CA
NZ
UK
AU
IND
US
A gene therapy developer recently shared early findings from a preclinical study assessing an experimental treatment for Alzheimer’s disease. The announcement focused on the effects of a single intravenous administration in a non-human primate model, providing initial insights into the therapy’s potential.
Ocugen (NASDAQ: OCGN) disclosed a binding term sheet that will enable the licensing of its OCU400 gene therapy, aimed at treating retinitis pigmentosa, across markets in the Middle East and North Africa. This step illustrates the company’s intent to broaden its global presence in …
Armata Pharmaceuticals advances its clinical pipeline with a regulatory green light for pediatric research. The company confirmed an agreement with U.S. Health authorities on a study plan for its investigational therapy targeting serious bacterial infections in children.
BiomX Inc. (NYSE American: PHGE) has taken steps to cancel 1,013,637 shares after identifying a violation of NYSE American’s listing requirements. The issue arose following the company’s recent acquisition activity, which fell under the exchange’s regulatory oversight. The shares in question were issued earlier …
Cue Biopharma (NASDAQ: CUE) announced a private placement that will add approximately $50.0 million to its balance sheet. Accredited investors, including notable asset managers, participated in the transaction.
Evaxion A/S (NASDAQ: EVAX) released fresh preclinical results for its cytomegalovirus (CMV) vaccine candidate EVX‑V1 at the International Herpesvirus Workshop in Montreal. The data highlight a novel, AI‑driven approach that could broaden the company's pipeline and influence investor sentiment as the share price dipped …
OmniAb Inc. Has named Amechi Nwachuku as its new Chief Operating Officer, marking a significant shift in its executive team. The appointment, effective July 13, 2026, follows a career spanning life sciences, diagnostics, and pharmaceuticals. Nwachuku’s role will focus on operational strategy as OmniAb …
A recent collaboration between Arovella Therapeutics and a contract research organization reflects increasing activity in the cell therapy field, particularly within oncology. The partnership demonstrates the rising need for specialized testing services in drug development, which may benefit firms involved in precision medicine.
Cerus Corp (NASDAQ: CERS), a company specializing in blood safety technologies, has announced a leadership transition by appointing its former chief executive to the role of Executive Chairman. The change became effective in the summer of 2026, marking a shift in the company’s executive …
DarioHealth Corp. (NASDAQ: DRIO) disclosed a shift in its executive leadership structure following an extended medical leave taken by its President and Chief Commercial Officer. The announcement outlines how the firm will navigate the interim period without the executive.
Please wait processing your request...